Kaoru Tamura

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

Hideyuki Arita, Kai Yamasaki, Yuko Matsushita et al. · Acta Neuropathologica Communications · 2016 · 265 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Recurrent mutations of <scp><i>CD79B</i></scp> and <scp><i>MYD88</i></scp> are the hallmark of primary central nervous system lymphomas

Taishi Nakamura, Kensuke Tateishi, T. Niwa et al. · Neuropathology and Applied Neurobiology · 2015 · 223 citations

Medicine, Molecular Genetics, Oncology +17

Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation

Kaoru Tamura, Masaru Aoyagi, Hiroaki Wakimoto et al. · Journal of neurosurgery · 2010 · 127 citations

Medicine, Oncology, Surgery +17

Stem Cells Loaded With Multimechanistic Oncolytic Herpes Simplex Virus Variants for Brain Tumor Therapy

Matthias Duebgen, Jordi Martínez‐Quintanilla, Kaoru Tamura et al. · JNCI Journal of the National Cancer Institute · 2014 · 122 citations

Medicine, Cell Biology, Oncology +17

TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma

Kenji Fujimoto, Hideyuki Arita, Kaishi Satomi et al. · Acta Neuropathologica · 2021 · 107 citations

Medicine, Molecular Genetics, Oncology +15